SCHEMBL21247149

SCHEMBL21247149

CC1(C)CCc2sc(NC(=O)c3ccc(NC4CCOCC4)cc3)c(C(=O)O)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.43
▸ CNR2 P34972 2/20 0.43
▸ TNF P01375 4/20 0.43
▸ NOD1 Q9Y239 4/20 0.43
▸ MEN1 O00255 8/20 0.41
▸ KMT2A Q03164 8/20 0.41
▸ MAPT P10636 7/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ GRIN2C Q14957 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ KLF5 Q13887 1/20 0.40
▸ GLO1 Q04760 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ FABP5 Q01469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21261111 0.85 CNR2 (0.37) CNR1CNR2FABP4FABP5
SCHEMBL21247099 0.85 RAB7A (0.56) TNFNOD1MEN1KMT2AMAPT
SCHEMBL21247146 0.82 LMNA (0.47) TNFNOD1MEN1KMT2AMAPT
SCHEMBL21253132 0.80 RAB9A (0.58) CNR1CNR2NOD1MEN1KMT2A
SCHEMBL21247283 0.80 TNF (0.61) CNR1CNR2TNFNOD1MEN1
SCHEMBL21247253 0.79 ALDH1A1 (0.43) TNFNOD1MEN1KMT2AMAPT
SCHEMBL21247299 0.78 TNF (0.46) CNR1CNR2TNFNOD1MEN1
SCHEMBL21247169 0.78 PTPN1 (0.53) TNFNOD1MEN1KMT2AMAPT
SCHEMBL21250159 0.77 CNR2 (0.52) CNR1CNR2TNFNOD1MEN1
SCHEMBL21247403 0.77 CFTR (0.51) MEN1KMT2AMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH CNR1 4561/4885CNR2 4405/4885TNF 1354/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH CNR1 4561/4885CNR2 4405/4885TNF 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback